anonymous
Guest
anonymous
Guest
Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products
December 07, 2015 02:00 AM Eastern Standard Time
LONDON--(BUSINESS WIRE)--Regulatory News:
Stallergenes Greer plc (the “Company”) (Euronext: STAGR)(Paris:STAGR), a biopharmaceutical company specialized in treatments for respiratory allergies, today communicated that its subsidiary, Stallergenes SAS (“Stallergenes”) is proceeding with a recall of allergy immunotherapy products which were shipped from its Antony (France) plant after August 13, 2015.
In France, this product recall is conducted according to a risk management plan agreed with the French Health Authority, l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). In other countries, the appropriate course of action will be discussed and agreed upon with each national Health Authority.
This follows a notification received by Stallergenes from the French Health Authority on December 2, 2015, as previously announced, arising from certain technical problems encountered following the launch of its new IT system in August 2015. Production is expected to resume when the Stallergenes’ IT system issues have been resolved and all observations made by the ANSM have been satisfactorily addressed.
December 07, 2015 02:00 AM Eastern Standard Time
LONDON--(BUSINESS WIRE)--Regulatory News:
Stallergenes Greer plc (the “Company”) (Euronext: STAGR)(Paris:STAGR), a biopharmaceutical company specialized in treatments for respiratory allergies, today communicated that its subsidiary, Stallergenes SAS (“Stallergenes”) is proceeding with a recall of allergy immunotherapy products which were shipped from its Antony (France) plant after August 13, 2015.
In France, this product recall is conducted according to a risk management plan agreed with the French Health Authority, l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). In other countries, the appropriate course of action will be discussed and agreed upon with each national Health Authority.
This follows a notification received by Stallergenes from the French Health Authority on December 2, 2015, as previously announced, arising from certain technical problems encountered following the launch of its new IT system in August 2015. Production is expected to resume when the Stallergenes’ IT system issues have been resolved and all observations made by the ANSM have been satisfactorily addressed.